Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Klaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg & Matthias H. Thomas. (2020) Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Current Medical Research and Opinion 36:9, pages 1559-1567.
Read now
Read now
NJ Mars, AM Kerola, MJ Kauppi, M Pirinen, O Elonheimo & T Sokka-Isler. (2019) Patients with rheumatic diseases share similar patterns of healthcare resource utilization. Scandinavian Journal of Rheumatology 48:4, pages 300-307.
Read now
Read now
Francesco Caso, Antonio Del Puente, Rosario Peluso, Paolo Caso, Nicolò Girolimetto, Aurora Del Puente, Raffaele Scarpa & Luisa Costa. (2016) Emerging drugs for psoriatic arthritis. Expert Opinion on Emerging Drugs 21:1, pages 69-79.
Read now
Read now
Articles from other publishers (22)
Saeed Mohammadpour, Samira Soleimanpour, Javad Javan-Noughabi, Nasrin Aboulhasanbeigi Gallehzan, Ali Aboutorabi, Reza Jahangiri, Rafat Bagherzadeh, Julia F. Gorman & Ali Nemati. (2022) A systemmatic literature review on indirect costs of women with breast cancer. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Crossref
Grace Yang, Inna Cintina, Anne Pariser, Elisabeth Oehrlein, Jamie Sullivan & Annie Kennedy. (2022) The national economic burden of rare disease in the United States in 2019. Orphanet Journal of Rare Diseases 17:1.
Crossref
Crossref
Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Prasheen Agarwal, Feifei Yang, Alexa P. Kollmeier, Elizabeth C. Hsia, Natalie J. Shiff, Bei Zhou, Chenglong Han, May Shawi, William Tillett & Philip J. Mease. (2022) The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial. Advances in Therapy 39:10, pages 4613-4631.
Crossref
Crossref
William Tillett, Laura C. Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems & Philip J. Mease. (2022) Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease 14, pages 1759720X2211408.
Crossref
Crossref
Bernd Schweikert, Chiara Malmberg, Örjan Åkerborg, Gayathri Kumar, Debby Nott, Sandeep Kiri, Christophe Sapin & Susanne Hartz. (2020) Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. PharmacoEconomics - Open 4:4, pages 635-648.
Crossref
Crossref
Juan D. Cañete, Joan M. Nolla, Ruben Queiro, Miguel J. Rodríguez, Miguel Ruiz & Luis Lizán. (2020) Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study. The Journal of Rheumatology 47:11, pages 1637-1643.
Crossref
Crossref
George BungeyStacey Chang-DouglassMing-Ann HsuJoseph C. CappelleriPamela YoungJohn Woolcott. (2020) Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States. Journal of Managed Care & Specialty Pharmacy 26:8, pages 1027-1038.
Crossref
Crossref
Bernd Schweikert, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla, Christophe Sapin & Susanne Hartz. (2020) Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open 10:8, pages e032552.
Crossref
Crossref
Neil McHugh, Áine Maguire, Ian Handel, William Tillett, James Morris, Neil Hawkins, Charlotte Cavill, Eleanor Korendowych & Farhan Mughal. (2020) Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs. The Journal of Rheumatology 47:5, pages 701-707.
Crossref
Crossref
Natalie Boytsov, Xiang Zhang, Kristin A. Evans & Barbara H. Johnson. (2019) Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis. PharmacoEconomics - Open 4:1, pages 105-117.
Crossref
Crossref
Adeline Ruyssen-Witrand, Richard Perry, Clare Watkins, George Braileanu, Gayathri Kumar, Sandeep Kiri, Debby Nott, Soyi Liu-Leage, Susanne Hartz & Christophe Sapin. (2020) Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open 6:1, pages e001117.
Crossref
Crossref
William Tillett, Chen-Yen Lin, Art Zbrozek, Aubrey Trevelin Sprabery & Julie Birt. (2019) A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire. Rheumatology and Therapy 6:3, pages 379-391.
Crossref
Crossref
Francesco Caso, Luisa Costa, Rosario Peluso, Antonio Del Puente & Raffaele Scarpa. 2019. Mosaic of Autoimmunity. Mosaic of Autoimmunity
527
540
.
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison, Robin Besuyen, Annegret Van der Aa, Neelufar Mozaffarian, Joy M Greer, Rebecca Kunder, Filip Van den Bosch & Dafna D Gladman. (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet 392:10162, pages 2367-2377.
Crossref
Crossref
Joseph F. Merola, Vivian Herrera & Jacqueline B. Palmer. (2018) Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clinical Rheumatology 37:10, pages 2751-2761.
Crossref
Crossref
Nicolas Iragorri, Mark Hofmeister, Eldon Spackman & Glen S. Hazlewood. (2018) The Effect of Biologic and Targeted Synthetic Drugs on Work- and Productivity-related Outcomes for Patients with Psoriatic Arthritis: A Systematic Review. The Journal of Rheumatology 45:8, pages 1124-1130.
Crossref
Crossref
M. Elaine Husni, Joseph F. Merola & Sara Davin. (2017) The psychosocial burden of psoriatic arthritis. Seminars in Arthritis and Rheumatism 47:3, pages 351-360.
Crossref
Crossref
Renata Linertová, Lidia García-Pérez & Iñigo Gorostiza. 2017. Rare Diseases Epidemiology: Update and Overview. Rare Diseases Epidemiology: Update and Overview
283
297
.
Vibeke Strand, Elaine Husni, Jenny Griffith, Zheng-Yi Zhou, James Signorovitch & Arijit Ganguli. (2016) Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. Rheumatology and Therapy 3:2, pages 305-322.
Crossref
Crossref
Paweł Kawalec, Krzysztof Piotr Malinowski & Andrzej Pilc. (2016) Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatology International 36:9, pages 1223-1230.
Crossref
Crossref
Dillon Kersh, Roselyn Kellen & Sharon Rose. (2016) The Annual Economic Burden of Psoriasis. Journal of Psoriasis and Psoriatic Arthritis 1:3, pages 112-122.
Crossref
Crossref
Azeen Sadeghian, Virginia Alldredge, Ardalan Minokadeh & Erin Boh. (2015) A Clinician's Guide to Diagnosing and Managing Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis 1:1, pages 9-25.
Crossref
Crossref